GSK's antibody-drug conjugate Blenrep has secured second-line approvals in Europe and Canada, marking a regulatory comeback for the targeted therapy. However, U.S. approval remains postponed due to ongoing dose optimization concerns raised by the FDA. This regulatory dichotomy underscores divergent global agency perspectives on the safety and dosing of new oncology therapies, affecting market access strategies for GSK.